# Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

> **NCT03289650** · PHASE3 · COMPLETED · sponsor: **Lorenzo Gallon** · enrollment: 29 (actual)

## Conditions studied

- End Stage Renal Disease
- Rejection of Renal Transplant

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** Tacrolimus Extended Release Oral Tablet [Envarsus]

## Key facts

- **NCT ID:** NCT03289650
- **Lead sponsor:** Lorenzo Gallon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-05
- **Primary completion:** 2021-02-23
- **Final completion:** 2021-02-23
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03289650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03289650, "Extended Release Tacrolimus vs. Twice-Daily Tacrolimus". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03289650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*